Video

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

Author(s):

Kathleen N. Moore M.D.
Conference|SGO Annual Meeting on Women's Cancer

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Related Videos
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with dark hair, smiling.
Image of woman with brown hair.
Image of man with grey hair.
Related Content
Palliative care text.
February 5th 2025

Palliative Care May Reduce Invasive Intervention Use in Early-Onset CRC

Roman Fabbricatore
Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of stomach.
February 3rd 2025

Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric/GEJ Cancer

Caroline Seymour
Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of stomach cancer.
February 1st 2025

Tevimbra Plus Chemotherapy May Improve Survival in First-Line ESCC

Courtney Flaherty
Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.
Illustration of intestines.
January 29th 2025

Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset

Russ Conroy
The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.